Gilotrif (Afatinib Dimaleate) Patent Expiration, LOE Window & CMS Spending

Gilotrif (Afatinib Dimaleate) by Boehringer Ingelheim: FDA Orange Book core substance LOE 2030-04-10 (last listed 2031-01-05), 2 AB generics, $66.1M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBoehringer Ingelheim
FDA Application & PathwayN201292 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2030-04-10
Last Listed Patent or Exclusivity Date2031-01-05
Orange Book Patents (*PED Extensions)10 patents (5 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$66.1M
2024 Medicare Part D Spend$61.1M
2024 Medicaid Spend$5.0M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 16.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.